Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2005

View Archived Issues

MSK-1 inhibitor shows potency and selectivity in biological testing

S1P3 antagonism may be useful in preserving epithelial integrity

K-201 affects renal hemodynamics in dogs

FDA lifts hold on clinical trials of Varisolve

Positive phase III results for PreHistin in preseasonal allergy treatment

Enrollment open in second phase I/II eczema study of NF-kappaB Decoy

IND submission for phase III study of Lauriad for oropharyngeal candidiasis

NicVAX European study completes enrollment

Merck achieves milestone using Transgene technology

Nabi's S. aureus type 336 vaccine enters clinical testing

PSN-357 for diabetes begins phase I trial

AERx HCQ program advances into phase II

MGI Pharma to acquire Guilford Pharmaceuticals

Cannabinoid CB1 agonists in early development at AstraZeneca

5-HT4 receptor agonists emerge from Dainippon R&D

Recent Wyeth patents report novel agents for thrombotic disorders

Novel PPARalpha agonist demonstrates superior lipid-lowering effects

Rozerem receives FDA approval for insomnia

Orphan drug designation recommended in Europe for brivaracetam

Lethality of UCN-01 increased by farnesyltransferase inhibitor in human multiple myeloma cells

Approvable letter for Entereg

New Adderall XR approval extends use to adolescents

Kayaku launches topic antifungal Lulicon

ZD-6474 shows promise in the treatment of NSCLC

Update on omalizumab in asthma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...